Coronary heart disease (CHD) carries significant morbidity and mortality worldwide. Elevated LDL-cholesterol and reduced HDL-cholesterol levels are well-recognized CHD risk factors. Despite guideline recommendations for intensive therapy among patients at high risk for CHD to lower LDL-cholesterol, such lowering has failed to prevent approximately two-thirds of cardiovascular events. As a result of new data, guidelines have begun to focus on non-HDL-cholesterol, HDL-cholesterol and triglycerides as treatment targets, with the end result being a recommendation for combination therapy, such as niacin plus statin for the treatment of dyslipidemia. Compared with statin monotherapy, a combination of niacin and statin therapy provides beneficial effects on a broad range of lipid particles and some evidence suggests a further reduction in CHD risk. Recent studies have shown that the combination of a fixed dose of extended-release niacin plus simvastatin reduces non-HDL-cholesterol, LDL-cholesterol, triglycerides and total cholesterol:HDL-cholesterol ratio by approximately 50% while increasing HDL-cholesterol by 25%. The safety of this combination is consistent with the safety profiles of each individual component and is well tolerated. A long-term study is currently being conducted to evaluate whether this combination therapy confers an additive impact on clinical end points.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1586/14779072.6.10.1303 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of niacin and omega-3 fatty acids on HDL-apolipoprotein A-I exchange in subjects with metabolic syndrome.
PLoS One
February 2024
Cardiovascular Research Center, Sanford Research, University of South Dakota, Sioux Falls, South Dakota, United States of America.
Article Synopsis
- This study examines how niacin and omega-3 fatty acids affect HDL-apolipoprotein A-I exchange (HAE), a function of HDL related to cholesterol transport, in individuals with metabolic syndrome.
- Over 16 weeks, participants received placebo, niacin (2g/day), omega-3 (4g/day), or a combination, with results showing significant increases in HAE for both niacin (15.1%) and omega-3 (11.1%) compared to placebo.
- Notably, omega-3 therapy showed increased HAE without raising traditional markers like HDL cholesterol or apoA-I levels, indicating the assay's ability to detect functional HDL changes independent of conventional measures.
Cholestatic Drug-Induced Liver Injury in a Patient Taking High-Dose Niacin for Hyperlipidemia.
J Investig Med High Impact Case Rep
January 2024
Mayo Clinic, Jacksonville, FL, USA.
Niacin, an important component of a balanced diet, is central to lipid metabolism. Occasionally used to treat hyperlipidemia, niacin is widely available without a prescription, making its use often unknown to treating physicians. Severe hepatotoxicity has been reported with niacin use.
View Article and Find Full Text PDFEffects of niacin on apo A1 and B levels: a systematic review and meta-analysis of randomised controlled trials.
Br J Nutr
April 2024
Oxford Brookes Centre for Nutrition and Health (OxBCNH), Department of Sport, Health Sciences and Social Work, Faculty of Health and Life Sciences, Oxford Brookes University, OxfordOX3 0BP, UK.
Niacin has been investigated for its potential impact on lipid metabolism and cardiovascular health. This meta-analysis aims to systematically evaluate the effects of niacin interventions on apo A1 and apo B levels, key regulators of lipoprotein metabolism and markers of cardiovascular risk. A comprehensive search of the literature was performed on five databases of PubMed, Scopus, Web of Science, Embase and Cochrane library, from inception up to 15 July 2023.
View Article and Find Full Text PDFEvaluating the Release of Different Commercial Orally Modified Niacin Formulations In Vitro.
Polymers (Basel)
July 2023
Department of Pharmaceutics, College of Pharmacy, Mercer University, 3001 Mercer University Drive, Atlanta, GA 30341, USA.
Objectives: To evaluate the release profile of different modified-release oral formulations of niacin, such as immediate-release (IR) powder and tablets, timed-release (TR) caplets, extended-release (ER) capsules, and controlled-release (CR) tablets, to assure their defined release pattern and correlate this release with their matrix polymers.
Significance: Niacin is used to manage hyperlipidemia by reducing cutaneous flushing and hepatotoxicity adverse events. The release profiles of different types of modified-release dosage forms depend on the types of coating materials (polymers) used in the matrix formation.
Magnetic Resonance Imaging of Intraplaque Hemorrhage and Plaque Lipid Content With Continued Lipid-Lowering Therapy: Results of a Magnetic Resonance Imaging Substudy in AIM-HIGH.
Circ Cardiovasc Imaging
November 2022
Department of Radiology, University of Washington, Seattle, WA (J.S., G.C., C.Y.).
Background: Intraplaque hemorrhage (IPH) is associated with plaque progression and ischemic events, and plaque lipid content (% lipid core) predicts the residual atherosclerotic cardiovascular disease risk. This study examined the impact of IPH on lipid content change in the setting of intensive lipid-lowering therapy.
Methods: In total, 214 AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome with Low High-Density Lipoprotein/High Triglycerides: Impact on Global Health Outcomes) participants with clinically established ASCVD and low high-density lipoprotein cholesterol received cartoid MRI at baseline and 2 years to assess changes in carotid morphology and composition.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!